Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country and market-access pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice.
Latin America is not opaque. Clinical-trial sites, commercial device registrations, and (separately) the people who run the work already sit on public government tools or on pages bioaccess® has already shipped. What is missing is one index that keeps the three graphs apart so a sponsor does not mix a first-in-human clock with a sanitary registro or a directory join form.
bioaccess® (a DBA of IMH ASSETS CORP.; Julio G. Martinez-Clark, Co-Founder & CEO) already publishes the operating products: First-in-Human CRO, LATAM Launch / market access, and the free join page at network.bioaccessla.com. This index is the public-data door, not a new SKU.
Graph 1 — Trials (registry activity, not bioaccess® studies)
On 1 September 2026 (6:32 PM ET) bioaccess® pulled ClinicalTrials.gov Data API v2 for interventional studies with at least one location in a named Latin American country. Official endpoint: clinicaltrials.gov/data-api/api. No API key. No HTML scrape. Counts are unique NCT IDs with ≥1 location in that country; multinational trials appear in every matching country. Unique OR across the country set: 17,497 interventional studies; 1,892 of those also carry InterventionType DEVICE.
| Country | All interventional | Device interventional |
|---|---|---|
| Brazil | 10,208 | 1,165 |
| Mexico | 5,160 | 241 |
| Argentina | 4,148 | 110 |
| Chile | 2,544 | 199 |
| Colombia | 1,911 | 116 |
| Peru | 1,238 | 35 |
| Panama | 346 | 38 |
| Dominican Republic | 234 | 25 |
| Costa Rica | 204 | 16 |
| Ecuador | 147 | 11 |
| Paraguay | 90 | 50 |
| Uruguay | 63 | 7 |
| El Salvador | 62 | 14 |
These numbers are registry activity. They are not a claim that bioaccess® ran the studies. They are not a site-chase list. The country-count table above is the only public count on this page.
National trial lists that already have a public, no-login face (open the government page; we will not scrape a login):
- Panama RESEGIS public project list — resegis2.integrait.co/index.php/listprojects. Snapshot cited on the live post Panama’s clinical-trial docket is a public Excel file (28 Aug 2026: 1,890 rows).
- Colombia INVIMA consulta — invima.gov.co/estudios (page text 12 Aug 2026: 1,157 studies). Official consolidado Excel also posted on the INVIMA biblioteca.
- Brazil ANVISA open-data ensaios CSVs — dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/ (TA_CONSULTA_ENSAIOS_CLINICOS and _LOCAIS). Medicines/biologics SCPC scope, not a complete device-trial dump.
- Argentina ANMAT EFC base — oficial XLSX through 30 Jun 2026.
- Chile ISP consulta — estudiosclinicos.ispch.gob.cl. ANDIM device-trial platform still “Próximamente” as of 31 Aug 2026.
Already live on bioaccessla.com for this graph: Independent LATAM early-phase industry tracker (July 2026, Phase 1 / Early Phase 1, industry-sponsored, start ≥ 1 Jan 2023 — narrower than the 1 Sep pull above). trial-evidence-registry is the published-case graph only. CT.gov FIH sites vs the CRO is an intercept hub, not a bulk directory.
Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. We pick the country the device needs.
Graph 2 — First registration / market access (titular, not a trial permit)
A sanitary registro and a trial authorization are different files. The visor or fila that names a holder is not an ethics clock. Live bioaccess® product page: bioaccessla.com/market-access (LATAM Launch Subscription, USD 7,500/year per country, first device family — already published). Country IoR rules: LATAM Importer of Record.
Official public lookups already opened (no unpublished holder invented):
- Mexico COFEPRIS Visor de Registros Sanitarios de Dispositivos Médicos — Comunicado 21/2026 (20 Aug 2026); tool at registros.cofepris.gob.mx/BRSDM. Operator page already live: COFEPRIS visor of active Mexico device registrations. The visor is JS; we do not publish a bulk CSV dump here.
- Brazil ANVISA FILA de análisis de dispositivos médicos — official CSV on dados.anvisa.gov.br. Not republished here as a download. Use the agency open-data page.
- Colombia INVIMA registros sanitarios DM — public consulta remains the agency pages. We do not republish those CSVs here.
- Chile ISP Decreto Exento N° 25 (2026) device-registration wave — live post chile-isp-decreto-exento-25-2026-device-registration.
Trial-authorization vs registro cuts already live (do not clone): El Salvador CNEIS vs DNM; ANMAT trial vs registro; Peru INS vs DIGEMID; Paraguay DINAVISA; Ecuador ARCSA. A trial permit is not a sanitary registro.
Graph 3 — Subcontractors (join page, not a fake member list)
The live join surface is network.bioaccessla.com. Homepage professional cards on that host are marketing. An anonymous read of the public contractors table on 28 Aug 2026 returned 0 rows. This page will not reprint those labels as verified members.
If you are a CRA, regulatory consultant, translator, SMO, or local RA firm: use the free join form on that host. Fallback published on the page: info@bioaccessla.com with name, country, specialty. Do not treat a marketing card as a subcontract.
What this index is not
- Not a harvest of PI emails. Facility-level emails stay off this page.
- Not PHI. No patient names, no implant dates, no imaging.
- Not unpublished clients. The evidence registry and case studies already name the public set; this page does not add names.
- Not a site-direct intercept. Campus kill-pages stay on their own family.
Contact: bioaccessla.com/contact. Book: book-a-meeting.
Julio G. Martinez-Clark, CEO · bioaccess®